STE (STERIS plc)
Insider Trading Activity
Every open-market purchase and sale reported by STE officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-12 | CHRISTOPHER S HOLLAND | Director | A | — | — |
| 2026-08-12 | Paul Edward Martin | Director | A | — | — |
| 2026-08-12 | Esther M. Alegria | Director | A | — | — |
| 2026-08-12 | CYNTHIA L FELDMANN | Director | A | — | — |
| 2026-08-12 | Mohsen Sohi | Director | MIXED | — | — |
| 2026-08-12 | Nirav R Shah | Director | A | — | — |
| 2026-08-12 | Pierre Boulud | Director | A | — | — |
| 2026-08-12 | Louis Shapiro | Director | A | — | — |
| 2026-07-02 | Mohsen Sohi | Director | MIXED | — | — |
| 2026-06-16 | John Adam Zangerle | Sr. VP, Gen Counsel, and Sec. | Sell | — | — |
| 2026-06-08 | Mary Clare Fraser | SVP & Chief HRO | F | — | — |
| 2026-06-08 | John Adam Zangerle | Sr. VP, Gen Counsel, and Sec. | F | — | — |
| 2026-06-08 | Renato Tamaro | V.P. & Corporate Treasurer | F | — | — |
| 2026-06-08 | Kenneth E Kohler | SVP & GM, AST | F | — | — |
| 2026-06-08 | Daniel A Carestio | President and CEO | MIXED | — | — |
| 2026-06-08 | Julia Madsen | Sr. VP and GM, Life Sciences | F | — | — |
| 2026-06-08 | Karen L Burton | Sr. Vice Pres., CFO | F | — | — |
| 2026-06-05 | Karen L Burton | Sr. Vice Pres., CFO | F | — | — |
| 2026-06-05 | Daniel A Carestio | President and CEO | F | — | — |
| 2026-06-05 | Mary Clare Fraser | SVP & Chief HRO | F | — | — |
| 2026-06-05 | Kenneth E Kohler | SVP & GM, AST | F | — | — |
| 2026-06-05 | Julia Madsen | Sr. VP and GM, Life Sciences | F | — | — |
| 2026-06-05 | Renato Tamaro | V.P. & Corporate Treasurer | F | — | — |
| 2026-06-05 | John Adam Zangerle | Sr. VP, Gen Counsel, and Sec. | F | — | — |
| 2026-06-04 | Richard C Breeden | Director | MIXED | — | — |
| 2026-06-04 | Pierre Boulud | Director | A | — | — |
| 2026-06-04 | Karen L Burton | Sr. Vice Pres., CFO | MIXED | — | — |
| 2026-06-04 | Daniel A Carestio | President and CEO | MIXED | — | — |
| 2026-06-04 | Mary Clare Fraser | SVP & Chief HRO | MIXED | — | — |
| 2026-06-04 | Kenneth E Kohler | SVP & GM, AST | MIXED | — | — |
| 2026-06-04 | Julia Madsen | Sr. VP and GM, Life Sciences | MIXED | — | — |
| 2026-06-04 | Cary L Majors | SVP and President, Healthcare | MIXED | — | — |
| 2026-06-04 | Lindsey McGowan | VP, Chf. Comp. & Quality Offc. | MIXED | — | — |
| 2026-06-04 | Renato Tamaro | V.P. & Corporate Treasurer | MIXED | — | — |
| 2026-06-04 | John Adam Zangerle | Sr. VP, Gen Counsel, and Sec. | MIXED | — | — |
| 2026-06-03 | Karen L Burton | Sr. Vice Pres., CFO | F | — | — |
| 2026-06-03 | Daniel A Carestio | President and CEO | F | — | — |
| 2026-06-03 | Mary Clare Fraser | SVP & Chief HRO | F | — | — |
| 2026-06-03 | Kenneth E Kohler | SVP & GM, AST | F | — | — |
| 2026-06-03 | Julia Madsen | Sr. VP and GM, Life Sciences | F | — | — |
| 2026-06-03 | Cary L Majors | SVP and President, Healthcare | F | — | — |
| 2026-06-03 | Lindsey McGowan | VP, Chf. Comp. & Quality Offc. | F | — | — |
| 2026-06-03 | Renato Tamaro | V.P. & Corporate Treasurer | F | — | — |
| 2026-06-03 | John Adam Zangerle | Sr. VP, Gen Counsel, and Sec. | F | — | — |
| 2026-03-06 | CYNTHIA L FELDMANN | Director | MIXED | — | — |
| 2026-01-06 | Lindsey McGowan | VP, Chf. Comp. & Quality Offc. | A | — | — |
| 2025-11-25 | Julia Madsen | Sr. VP and GM, Life Sciences | MIXED | — | — |
| 2025-11-20 | Renato Tamaro | V.P. & Corporate Treasurer | MIXED | — | — |
| 2025-11-13 | John Adam Zangerle | Sr. VP, Gen Counsel, and Sec. | MIXED | — | — |
| 2025-10-08 | Daniel A Carestio | President and CEO | Sell | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | President and CEO | 240,200 | — |
| — | Director | 126,334 | — |
| — | President & CEO | 117,606 | — |
| — | President and CEO | 68,075 | — |
| — | Director | 67,687 | — |
| — | Senior Vice President | 56,528 | — |
| — | Sr. Vice Pres., CFO | 47,483 | — |
| — | Sr. VP, Gen Counsel, and Sec. | 35,259 | — |
| — | SR VP & Grp. Pres., Healthcare | 35,050 | — |
| — | Sr. VP. Surgical Solutions | 32,037 | — |
| — | Director | 31,223 | — |
| — | Director | 29,156 | — |
| — | Director | 28,363 | — |
| — | Director | 26,438 | — |
| — | Sr. V P, Healthcare Spec Serv | 25,119 | — |
| — | Sr. VP, Gen Counsel, and Sec. | 24,651 | — |
| — | Sr.V. P. & C.C.O. | 24,428 | — |
| — | Sr. VP & Chief Tech. Officer | 19,115 | — |
| — | Sr. VP, Govt. & Administration | 18,700 | — |
| — | SVP and President, Healthcare | 17,472 | — |
| — | Director | 16,631 | — |
| — | Sr. V.P., Procedural Solutions | 14,685 | — |
| — | SVP & Chief HRO | 13,716 | — |
| — | Sr. Vice Pres., CFO | 13,184 | — |
| — | Sr. V.P., IPT | 13,162 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the STE quote page; the site-wide leaderboard is on the insider transactions hub.